Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
5 Different ways Macintosh is Prepared to Overwhelm Gaming, Even Against Windows - 2Lower-cost space missions like NASA's ESCAPADE are starting to deliver exciting science – but at a price in risk and trade‑offs
- 3Pick Your #1 Kind Of Bread
- 4Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- 5Remain Fit: Powerful Wellness and Work-out Schedules for a Better You
- Home Wellness Basics: Building Your Home Exercise center
- Idris Elba is the king of the stress-watch
- Washington state experiences historic flooding as Skagit River hits record high level. See flooding maps, highway closures and forecasts.
- Should you get an RSV vaccine this fall? What to know and where to get a shot
- Instructions to Clean and Really focus on Your Lab Precious stone
- Bayer sues COVID vaccine makers over mRNA technology
- Instructions to Boost Your True capacity with a Brain research Degree
- Make your choice for the music application with the most amicable connection point!
- 'A prank': Israel Police detain suspect for shooting rubber bullets at Ashkelon kindergarten
